| Name | Title | Contact Details |
|---|
Catasys leads the health care industry in improving health and reducing claims costs for health plan members with behavioral health disorders that cause or exacerbate co-existing medical conditions. OnTrak™, a 52-week intensive outpatient program, treats an overlooked population: members suffering from chronic disorders such as substance dependence, anxiety and depression who rarely seek care. These members cost health plans millions of medical dollars primarily due to preventable ambulance usage, medical ER visits and medical inpatient admissions. Catasys uses a proprietary analytics platform and predictive modeling to identify high utilizers of medical healthcare services with costs that can be significantly reduced by addressing the underlying behavioral health disorder(s). Through proactive outreach, we engage and treat these individuals in our patient-centric program that integrates evidence-based medical interventions, psychosocial skill building and care coaching by nurses.
Radiology Imaging Associates (R.I.A.) is a Clinton, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Draeger Safety Pacific is a supplier of high quality respiratory protection, including single and dual filter masks as well as different material options to suit all customer requirements.
Interstate Blood Bank Inc is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.